ArticleThe journal of allergy and clinical immunology. In practice2023
Risk-stratified management to remove low-risk penicillin allergy labels in the patients with COVID-19 in the intensive care unit.
Abstract read
In one paragraph
Article in The journal of allergy and clinical immunology. In practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review and meta-analysis of interventions to delabel low-risk penicillin allergies with consideration for sex and gender.British journal of clinical pharmacology · 2025Pooled it
- The Pragmatic Removal of Penicillin Allergy Electronic Health Record Labels (PROPEL) Trial: A Randomized Clinical Trial.The journal of allergy and clinical immunology. In practice · 2025Trial
- Oral challenge vs routine care to assess low-risk penicillin allergy in critically ill hospital patients (ORACLE): a pilot safety and feasibility randomised controlled trial.Intensive care medicine · 2024Trial
- Evaluating penicillin allergy clinical decision-making tools to enhance penicillin allergy delabeling.The journal of allergy and clinical immunology. Global · 2026Article
- Inpatient Penicillin Allergy Delabeling: "How Soon Can We Get Started?"The journal of allergy and clinical immunology. In practice · 2025Article
- Clearance of penicillin allergies via direct oral provocation testing (DOPT): a systematic review.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
- Patient-related factors impact the implementation of inpatient antibiotic allergy delabeling.The journal of allergy and clinical immunology. Global · 2024Article
- A call to address penicillin allergy labels in patients with hematopoietic stem cell transplants: How to avoid rash decisions.Transplant infectious disease : an official journal of the Transplantation Society · 2024Review
- A multicentre observational study to investigate feasibility of a direct oral penicillin challenge in de-labelling 'low risk' patients with penicillin allergy by non-allergy healthcare professionals (SPACE study): Implications for healthcare systems.The Journal of infection · 2024Observational
- Penicillin allergy de-labelling by non-allergists: a comparison of testing protocols.JAC-antimicrobial resistance · 2023Review
- Assessing Low-Risk Penicillin Allergies in Critical COVID-19, A Novel Perspective on an Emerging Antibiotic Allergy Opportunity.The journal of allergy and clinical immunology. In practice · 2023Article
- Differences in beta-lactam and penicillin allergy: Beyond the West and focusing on Asia-Pacific.Frontiers in allergy · 2022Review
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Joanna L StollingsDepartment of Pharmaceutical Services, Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tenn.
Grace KooDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn.
Christopher J LindsellDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, Tenn.
Mary Lynn DearVanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tenn.
Allison McCoyDepartment of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tenn.
Todd W RiceDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn.
Elizabeth J PhillipsDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tenn; Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tenn; Institute for Immunology & Infectious Diseases, Murdoch University, Murdoch, WA, Australia.
Cosby A StoneDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn. Electronic address: cosby.a.stone@vumc.org.
Vanderbilt Learning Healthcare System Investigators
Funding
Immune Tolerance Network UM1 2023 SupplementUM1AI109565 · NIAID · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI Mark S Anderson, Jane Hoyt Buckner · 2014 to 2026
$451.6MVanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7MNATIENS: A Phase III Randomized Double Blinded Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisU01AI154659 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2020 to 2025
$15.5MCLINICAL PHARMACOLOGY TRAINING PROGRAMT32GM007569 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Bjorn C Knollmann · 1985 to 2026
$12.4MGenetic risk and long-term outcomes associated with Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in survivorsR01HG010863 · NHGRI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2019 to 2022
$3.1MLearning Health System Scholar Program at VanderbiltK12HS026395 · AHRQ · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ROTHMAN, RUSSELL L., ROUMIE, CHRISTIANNE L. · 2018 to 2022
$2.7MImmune-mediated adverse drug reactions to HIV and TB treatments in South Africa: predict, prevent and improve long-term outcomes (IMARI SA study)R01AI152183 · NIAID · UNIVERSITY OF CAPE TOWN · PI MEINTJES, GRAEME AYTON, PHILLIPS, ELIZABETH · 2020 to 2025
$1.6MStevens-Johnson syndrome/toxic epidermal necrolysis 2021: Collaboration, Innovation and CommunityR13AR078623 · NIAMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2021 to 2021
$33kAHRQ HHS K12 HS026395NCATS NIH HHS UL1 TR002243NHGRI NIH HHS R01 HG010863NIAID NIH HHS R01 AI152183NIAID NIH HHS U01 AI154659NIAID NIH HHS UM1 AI109565NIAMS NIH HHS R13 AR078623NIGMS NIH HHS T32 GM007569
Abstract
PubMed holds no abstract for this paper.
Indexed as
COVID-19Drug HypersensitivityHypersensitivityAnti-Bacterial AgentsHumansIntensive Care UnitsPenicillinsAnti-Bacterial AgentsPenicillins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.